Ophthalmology Search
Ophthalmology Ophthalmology
age-related%20macular%20degeneration
AGE-RELATED MACULAR DEGENERATION
Age-related macular degeneration is a common, chronic, progressive, degenerative disease that causes central loss of vision due to abnormalities that occurs in the pigment, neural and vascular layers of the macula.
The macular disorder may have one or more of the following:
- Formation of drusen which are localized deposits of extracellular material usually concentrated in the macula
- Abnormalities in the retinal pigment epithelium (eg hypopigmentation or hyperpigmentation)
- Retinal pigment epithelium and choriocapillaris geographic atrophy
- Neovascular (exudative) maculopathy
Decreased central vision and distortion of seeing straight lines are the most common symptoms.

Follow Up

  • Monocular near vision (using Amsler grid) monitoring should be done in each follow-up exam

Schedule of Follow-up

  • Non-neovascular age-related macular degeneration (AMD)/Intermediate or Advanced AMD in antioxidant vitamin and mineral supplements
    • At 6-24 months after treatment if asymptomatic
    • Advise immediate consultation if new symptoms suggestive of choroidal neovascularization (CNV) occurs
  • Subfoveal neovascular AMD in Ranibizumab therapy
    • Approximately 4 weeks after treatment
    • Subsequent return will be based on the clinical findings
  • Subfoveal neovascular AMD in Pegaptanib sodium therapy
    • Every 6 weeks with retreatments as indicated
  • Subfoveal neovascular AMD after photodynamic therapy (PDT) with Verteporfin
    • Every 3 months until stable, with retreatments as indicated
  • Extrafoveal neovascular AMD after laser photocoagulation therapy
    • At 2-4 weeks after treatment with fundus fluorescein angiography (FFA) and then 4-6 weeks thereafter
Editor's Recommendations
Most Read Articles
Beta-blockers may reduce mortality in patients with heart failure, renal dysfunction
Roshini Claire Anthony, 4 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
Physician–pharmacist collaborative care improves nb-DMARD dose optimization, adherence
Stephen Padilla, 5 days ago
Implementation of the collaborative care in a rheumatoid arthritis (RA) clinic has led to improvements in nonbiologic disease-modifying antirheumatic drugs (nb-DMARDs) optimization, adherence to safety recommendations on nb-DMARD monitoring and detection of adverse drug events in RA patients, according to a Singapore study.
Menopausal HRT and breast cancer: 1 million already at risk
Pearl Toh, 6 days ago
Use of menopausal hormone therapy (MHT) was associated with a significantly increased risk of invasive breast cancer, which became progressively greater with longer duration of use, a meta-analysis of worldwide prospective epidemiological studies has shown.
Early-life exposures affect BP in children
4 days ago
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.